C Diff Treatment

Clostridioides difficile infection (CDI) is a common nosocomial infection and is an urgent threat to public health. Vancomycin is the preferred antibiotic treatment for CDI but is associated with recurrence. Lactobacillus rhamnosus GG is an adjunctive treatment for gastroenteritis and …

Emerging metronidazole and vancomycin resistance in Clostridioides difficile. Is this impacted by current oral vancomycin dosing? https://t.co/RQfpNBTuZc #IDTwitter #TwitteRx #cdiff pic.twitter.com/Kl0FVCuIY8— Metro Infectious Disease Consultants (@MIDCUSA) May 3, 2022

Omadacycline exhibited potent in vitro activity against C. difficile and showed efficacy in a model of C. difficile-associated diarrhea.

The RCT was preregistered at EudraCT (j.no. 2015-003004-24, https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003004-24/results) and at ClinicalTrials.gov (study identifier NCT02743234, https://clinicaltrials.gov/ct2/show/NCT02743234).

Fidaxomicin, now commonly used to treat Clostridioides difficile infection, selectively targets the bacterium while sparing crucial gut commensals that protect against colonization. However, knowledge gaps in the molecular basis of its narrow-spectrum activity remain.

There are several emerging treatments for C difficile infections.

Navigating the 2021 update to the IDSA/SHEA Clostridioides difficile guidelines: An ethical approach to equitable patient care - Volume 2 Issue 1

Researchers at University of California San Diego School of Medicine and Jacobs School of Engineering, with colleagues at Baylor College of Medicine, have used a systems biology approach to parse the ...

The researchers wrote that their findings showcase the need for close monitoring of patients and for effective treatments for those with recurrent infection, which occurs in 15%-30% of all patients with Clostridioides difficile.

The Centers for Disease Control and Prevention continues to classify C. difficile as an urgent threat given the great burden on patients and the healthcare system. This Gram-positive bacterium causes diarrhea, abdominal bloating, and colitis in addition to significant morbidity and mortality, increased healthcare costs, and hospital readmission rates. In response to accumulating clinical trial evidence and real-world data, guideline recommendations on the selection of antimicrobial therapy have changed. Clinicians may not be familiar with these changes in the selection and application of antimicrobial therapies for treating initial and recurrent CDI.

About 65% of patients with metronidazole-resistant recurrent C difficile infection benefitted from taking rifaximin.

We are looking to hire a postdoc @UNSWMedicine to work with us on the #microbiome immunoglobulin degradation & microbial transplants. Will have access to cool samples and data from FOCUS & LOTUS #FMT studies in #ulcerativecolitis please RT if relevant. https://t.co/SfGVb49rhr— Nadeem Kaakoush (@NOKaakoush) April 20, 2022

A large proportions of patients with C difficile infections do not respond to metronidazole.

New research shows diarrhea did not increase overall mortality for hospitalized patients.

The therapeutic effect of Clostridium butyricum for adults with Clostridioides difficile infection (CDI) was investigated. A retrospective study was conducted in medical wards of Tainan Hospital, Ministry of Health and Welfare, between January 2013 and April 2020. The disease severity …

Background Clostridium difficile infection (CDI) is a leading cause of hospital-acquired diarrhea. Rifaximin is an antibiotic that offers marginal resistance to C. difficile bacteria. This st...

Concomitant antibiotic (CA) use for infection treatment is a major risk factor for recurrent C difficile infection. One SHEA 2022 study examined whether fidaxomicin or vancomycin would be more beneficial for CA patients.

Concomitant antibiotic (CA) use for infection treatment is a major risk factor for recurrent C difficile infection. One SHEA 2022 study examined whether fidaxomicin or vancomycin would be more beneficial for CA patients.

The study aims to add a new and beneficial perspective using Immunoinstant G food supplement as an adjuvant treatment. It is essential to study the bibliographic resources in the field to identify the current stage of knowledge on this topic. For this purpose, we have prepared a systematic literatur …

This study is registered with clinicaltrials.gov (Identifier: NCT02667418).

We observed that fidaxomicin and bezlotoxumab are prescribed in similar clinical scenarios, although those treated with bezlotoxumab have greater comorbidity. The proportion of recurrences was numerically lower in those treated with bezlotoxumab, although the propensity analysis did not find signifi …

Nature - Structural analysis of Clostridioides difficile RNA polymerase in complex with fidaxomicin combined with biochemical, genetic and bioinformatic analyses identifies a key residue that...

Fidaxomicin (Fdx) is widely used to treat Clostridioides difficile (Cdiff) infections, but the molecular basis of its narrow-spectrum activity in the human gut microbiome remains unknown. Cdiff infections are a leading cause of nosocomial deaths1. Fidaxomicin, which inhibits RNA polymeras …

Fidaxomicin (Fdx) is widely used to treat Clostridioides difficile (Cdiff) infections, but the molecular basis of its narrow-spectrum activity in the human gut microbiome remains unknown. Cdiff infections are a leading cause of nosocomial deaths1. Fidaxomicin, which inhibits RNA polymeras …

Nature - The RNA polymerase of the bacterial pathogen Clostridioides difficile is selectively targeted by the antibiotic fidaxomicin.

Most antibiotics are double-edged swords. Besides killing the pathogen they are prescribed for, they also decimate beneficial bacteria and change the composition of the gut microbiome. As a result, patients ...

Both fidaxomicin and vancomycin are recommended for treatment of Clostridioides difficile infections, but real-world data suggest fidaxomicin should be the go-to treatment option.